Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onward and upward

Biotech winners, losers in 2Q17

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from the first quarter, with the bottom two market cap tiers both losing ground.

Large cap biotechs valued at $10 billion and up posted a median increase of 4.2% and gained nearly $47 billion in aggregate equity value (see “Results by Market Cap”).

Regeneron Pharmaceuticals Inc. led the charge with a 27% gain after U.S. and EU approval of Kevzara sarilumab to treat rheumatoid arthritis and FDA approval of a new once-monthly dosing schedule for hypercholesterolemia drug Praluent alirocumab. Both Kevzara, a mAb against IL-6 receptor, and Praluent, a mAb against PCSK9, are partnered with Sanofi.

Regeneron also got a bump late in the quarter on data from a Phase III trial comparing its wet age-related macular degeneration (AMD) drug Eylea aflibercept to brolucizumab from Novartis AG. While the trial found brolucizumab non-inferior to Eylea, multiple analysts and investors noted that putting the milestone in the rearview mirror removed an overhang on Regeneron’s stock.

UCB S.A. posted the only double-digit loss among large caps, with shares off 17% on the quarter on a cardiovascular safety signal in the Phase III ARCH trial of Evenity romosozumab to treat postmenopausal osteoporosis. Evenity has a PDUFA date of July 19, but UCB and partner Amgen Inc. have said they no longer expect FDA to approve the mAb against sclerostin.

The $5-$9.9 billion band performed best among the five tiers, surging to a 10.2% median gain and adding $6.7 billion in total market value.

Read the full 2721 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE